Fennec Pharmaceuticals Inc.

Good morning, ladies and gentlemen. Welcome to FENIC Pharmaceuticals' fourth quarter and four-year 2025 earnings and corporate update conference call. At this time, all participants are on a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now I'd like to turn the conference over to FENIC's Chief Financial Officer, Robert Andrade.

Thank you, Operator. and good morning, everyone. Thank you for joining us today. We are pleased to host Phenix Pharmaceuticals' fourth quarter and full year 2025 earnings conference call, during which we will review our financial results as well as provide a general business update. Towards the end of the call, we will conduct a Q&A session hosted by myself, starting with frequent questions that the company receives from investors. followed by our traditional open Q&A session. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Medical Officer, Dr. Pierre Sayad. Pierre is an accomplished industry executive with proven success leading global medical teams and oncology launches at companies such as Onyx Pharmaceuticals Keriopharm Therapeutics, Oncopeptides, and BTI Biopharma. Dr. Syed is a graduate of the School of Medicine of Loma Linda University, as well as a Harvard Business School alum. Since joining Fennec in the fourth quarter of 2024, Pierre has been instrumental in advancing our medical strategy and clinical evidence strategy. expanding engagement with leading institutions and key opinion leaders, and strengthening the independent data foundation supporting PEDMARC. Later in the call, Pierre will speak to the substantial progress being made on the medical front and the importance of the medical team in the education process of CIO and PEDMARC. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. References to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. SEC. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com. where it will be available for the next 30 days. And with that, I'll turn the call over to our CEO, Jeff Hackman.

Thank you, Robert. Good morning, everyone. Hey, thanks for joining us today on a very special earnings call. 2025 was a transformational year for Fennec. We delivered record net product sales of 44.6 million. compared to $29.6 million in 2024. But most importantly, this growth was really driven by quarter-over-quarter expansion with our active patients as well as new and existing accounts. This reinforces the durability and demand and the effectiveness of our overall market development strategies. In the fourth quarter, given the positive momentum we saw in 2025, we made the strategic decision to further enhance our execution by increasing our customer-facing team and to try to achieve a much greater reach and frequency with our customers so we can ultimately help more cancer patients protect their hearing. We expanded our capabilities to include new territories in high prescribing targets in the AYA or adolescent and young adult market. We strengthened the company's financial health during the year with discipline operating decisions and efficiency measures, including the closing of public offerings, raising over 42 million in net proceeds, which resulted in the full redemption of our debt. We were intentional in our capital allocation, focused on high-impact initiatives, and continued to enhance our operating leverage as our business scaled. This balanced approach in investing in growth while maintaining financial rigor has positioned us well for long-term value creation, with the strongest balance sheet right now in the company's history. Our full-service patient support program, I've mentioned before in the past, FENIC HEARS, which is designed to simplify access and support continuity of care by guiding patients through coverage, reimbursement, and providing free product for eligible individuals, as well as coordinating a nurse-led administration and at-home infusion services, achieved a record performance in the fourth quarter. The program reached all-time highs in patient enrollments, prescribed and infused vials, active patients and conversion rates. In fact, conversion rates were up 70% in Q4 compared to 50% in the first quarter. These results reflect not only patient need but the exceptional execution of our field organization and our operational infrastructure that we have built to ensure appropriate and efficient access for our patients. Now, as we continue to increase the awareness and use of PEDMARK through our sales activities, our marketing team has been busy as well, expanding focus to activate young adult testicular patients, for example, on a broader scale. In the coming quarter, we're excited to launch an initiative around the Indy 500 race in May in close partnership with a testicular cancer advocacy group. Following that, we will also have a significant presence this year at the ASCO meeting in Chicago. We look forward to providing more updates on these initiatives and others in months ahead. Beyond commercial performance and our activities, we also made significant progress advancing our clinical evidence strategy. Shortly, you're going to hear from Pierre. He'll provide you much more details on the progress and how we are moving these forward in our medical affairs initiatives. Finally, top line results from our investigator-initiated phase two slash three, we call it STS-J01 clinical trial for PEDMARC in Japan, is progressing well. This, as you guys know, we believe it's still early, but this clinical milestone is very important for FENIC and reinforces the broader applicability of PEDMARC and the opportunity to expand our impact globally, partnering and registering this product in Japan and potentially broader in Asia. As a reminder, PEDMARC is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors and is also recognized by the National Comprehensive Cancer Network, or the NCCN, with a 2A recommendation for use in AYA patients. Now I'd like to just take a moment to thank our dedicated employees for their focus this past year. Their resilience and their belief in our mission, it's been instrumental in driving our performance. We've built a very strong organization with strong revenue growth and notable milestone achievements during the quarter. And the year further will validate our strategic plans and objectives and market development strategies, and importantly, Fennec's ability to execute our plans. Further, I'm proud of our executive team and each of their respective operating functions at Fennec. Overall, we had a strong performance and strong foundation that we built in 2025, and that is going to propel us and propel Fennec into the next chapter of this organization. And this next chapter is going to be defined, as I mentioned, with execution, global expansion, and sustained growth. So with that, let me turn it over to Pierre.